Possible safer target for anti-clotting drugs foundSeptember 27, 2007Researchers at the University of Illinois at Chicago College of Medicine have identified a new molecular target in blood clot formation, which seems to reduce clotting without excessive bleeding, the common side-effect of anti-clotting agents. The findings are reported in the September issue of Molecular and Cellular Biology. "It was very surprising to find an enzyme whose inhibition lessened platelet aggregation without abnormal bleeding, and we immediately realized that it could have very important implications for the treatment of cardiovascular disease," said Shafi Kuchay, a graduate student in pharmacology and first author of the paper.
When clots form, small blood cells called platelets begin to clump together. Aspirin and other anti-clotting agents reduce the risk of heart attack and stroke by blocking the biochemical pathway that causes platelets to become sticky. But all these drugs put patients at risk of excessive bleeding. The UIC researchers made a mouse model that lacked a gene for a protease enzyme most commonly found in blood cells called calpain-1, in order to determine its function. They found that mice lacking calpain-1 had reduced platelet aggregation but did not have any abnormal bleeding. The mice lacking calpain-1 (called "knockout" mice) had increased levels of another enzyme, known as protein tyrosine phosphatase-1B. When the mice were given a PTP1B inhibitor, the reduced platelet aggregation was restored. When calpain-1 knockout mice and mice lacking PTP1B were crossed to create double-knockout mice, platelet aggregation was restored in the offspring that lacked the genes for both enzymes. The researchers were thus able to establish that PTP1B turns off the signal for platelet aggregation and that calpain-1 regulated the amount and activity of this "off switch." "Because of the danger of excessive bleeding, people taking anti-clotting medications are monitored carefully and warned not to exceed their recommended doses," said Dr. Athar Chishti of the UIC Cancer Center, and senior author of the study. "Our research unveils a new molecular target for anti-platelet drugs, which may avoid the dangerous side-effects of the current drugs." In a secondary, serendipitous finding, the fact that the calpain-1 knockout mice have elevated PTP1B levels may prove important to research into diabetes and obesity. "Mice that lack the gene for PTP1B have been known for some time to display increased insulin sensitivity and resistance to diet-induced obesity," said Chishti, who is professor of pharmacology. He noted that PTP1B inhibition has already been identified as a therapeutic goal by many researchers in diabetes and obesity. "Our calpain-1 knockout mice with their elevated PTP1B levels offer a good model system for testing the potency of novel PTP1B inhibitors," he said. University of Illinois at Chicago | |||||||||||||||||||||
|
Related Platelet Aggregation Current Events and Platelet Aggregation News Articles Triple antiplatelet therapy appears superior to dual antiplatelet therapy Results of five research studies and a clinical registry first-report presentation scheduled for the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), suggest that triple antiplatelet therapy for patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents achieves greater platelet inhibition than conventional dual antiplatelet therapy. Safety of antithrombotic treatment in acute coronary syndromes The management of acute coronary syndromes (with or without ST segment elevation) requires the use of anticoagulants, antiplatelet agents (aspirin, clopidogrel and/or glycoprotein (GP) IIb/IIIa inhibitors), beta-blockers, thrombolytics in some cases, and revascularization / reperfusion. Study shows pine bark naturally reduces cardiovascular risk factors in diabetics A new study published in the May 2008 (volume 8, issue 25) edition of the journal of Nutrition Research shows Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, reduces blood sugar in type II diabetes patients, allows people to lower their antihypertensive medication and improves cardiovascular disease (CVD) risk factors. Ibuprofen Destroys Aspirin's Positive Effect on Stroke Risk Stroke patients who use ibuprofen for arthritis pain or other conditions while taking aspirin to reduce the risk of a second stroke undermine aspirin's ability to act as an anti-platelet agent, researchers at the University at Buffalo have shown. Researchers determine timing of administration of platelet-inhibiting drugs Clinicians should carefully weigh the risks and benefits of when to administer platelet glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors for patients with acute coronary syndromes undergoing invasive treatment. MIT material stops bleeding in seconds MIT and Hong Kong University researchers have shown that some simple biodegradable liquids can stop bleeding in wounded rodents within seconds, a development that could significantly impact medicine. Pine tree bark reduces diabetic leg ulcers Untreated diabetic leg ulcers may result in amputations. According to the Center of Disease Control, one out of six diabetics will require an amputation (below the knee) during their lifetime. Green tea and the 'Asian Paradox' There is a lower incidence of cardiovascular disease and cancer in Asia where people smoke heavily, which may be accounted for by high consumption of tea, particularly green tea, according to a review article published by a Yale School of Medicine researcher. Scientists discover two genes linked to early heart attack risk One of the genes, known as VAMP8, normally expresses a protein essential for early stages of clotting. When clotting occurs in a coronary blood vessel, it can lead to heart attack. Hopkins study shows low-dose aspirin suppresses clumping of blood platelets in both sexes A once-daily pill of low-dose aspirin helps lower the potential for clot-forming blood cells-in both men and women-to stick together in narrow blood vessels, a study from Johns Hopkins shows. More Platelet Aggregation Current Events and Platelet Aggregation News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||